October 17th 2024
The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute myeloid leukemia.
Exploring Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With AML
April 6th 2017Sudipto Mukherjee, MD, assistant staff, Gaussig Cancer Institute, Cleveland Clinic, discusses a study exploring eltrombopag to enhance platelet count recovery in elderly patients with acute myeloid leukemia (AML).
Watch
Immune Checkpoint Approaches in AML and MDS: A Next Frontier?
March 7th 2017The researchers discuss the rationale for checkpoint-based therapies including antibodies to PD-1/PD-L1 and CTLA-4, an overview of clinical experience with these agents, and future considerations and combinations of these agents.
Read More
Early Signs of Activity From Lirilumab/Azacytidine Combo in Heavily Pretreated AML
December 6th 2016The combination of lirilumab and azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia (AML), according to phase Ib/II findings presented at the 2016 ASH Annual Meeting.
Read More
Vadastuximab Talirine Shows Early Signs of Efficacy in Patients With AML
December 5th 2016With treatment for newly diagnosed acute myeloid leukemia remaining essentially unchanged over the last 4 decades, researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for these patients.
Read More
CPX-351 Before Transplant Improves Survival for Older Patients With AML
December 4th 2016An exploratory subgroup analysis of older patients with high-risk acute myeloid leukemia who took the liposomal formulation CPX-351 (Vyxeos) before allogeneic hematopoietic cell transplantation demonstrated that the drug improves overall survival and reduces the risk of early death.
Read More
An Overview of the PROGRESS II Trial in Acute Leukemia and Myelodysplastic Syndrome
December 4th 2016Miguel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, and director, Adult Bone Marrow Transplantation Fellowship Program, gives an overview of the PROGRESS II trial in acute leukemia and myelodysplastic syndrome during the ASH Annual Meeting.
Watch
Ponatinib Granted FDA Approval for Rare Leukemias
November 30th 2016The FDA has granted a full approval and label update to ponatinib (Iclusig) for patients with chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Read More
Midostaurin Granted Priority Review for AML, Systemic Mastocytosis
November 15th 2016The FDA has granted a priority review to the multikinase inhibitor midostaurin as a treatment for patients with newly-diagnosed <em>FLT3</em>-mutated acute myeloid leukemia or advanced systemic mastocytosis.
Read More
Immunotherapy May Be Next Frontier for AML, Says Daver
September 16th 2016Immunotherapy offers promise in acute myeloid leukemia (AML), a disease type which has not seen significant progress in many years, said Naval G. Daver, MD, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Read More
Pracinostat Receives Breakthrough Designation from FDA for Treatment of AML
August 2nd 2016Pracinostat has received a breakthrough therapy designation from the FDA, when given in combination with azacitidine, for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) aged 75 years or older, or for those who are ineligible for intensive chemotherapy, according to MEI Pharma, the company developing pracinostat.
Read More
The Role of FLT3 Inhibitors in Acute Myeloid Leukemia
July 27th 2016Raoul Tibes, MD, PhD, physician-scientist at the University Hospital Head Myeloid Malignancies, Department of Internal Medicine II at the University Hospital in Würzburg, and adjunct consultant at Mayo Clinic, discusses the role of FLT3 inhibitors in the treatment of patients with acute myeloid leukemia.
Watch
Patients with Chronic Phase CML Can Safely Conclude TKI Treatment
July 22nd 2016Patients with chronic phase chronic myeloid leukemia (CML) can safely conclude treatment of tyrosine kinase inhibitors (TKIs) following a maintained deep molecular remission, according to findings from the large EURO-SKI trial presented at the 2016 European Hematology Association (EHA) Congress.
Read More
Final Results for Phase III Trial of CPX-351 Reveal Reduced Mortality Risk in AML
July 22nd 2016Final data from a phase III trial of CPX-351 (Vyxeos) in older patients with high-risk, secondary acute myeloid leukemia (AML) revealed that CPX-351 reduced the mortality risk by 31% compared with cytarabine and daunorubicin (7+3), according to findings presented at the 2016 ASCO Annual Meeting.
Read More
CAR Therapy Yields High Complete Response Rates in Adults with B-cell ALL in Phase I Trial
June 9th 2016Infusion with 19-28z chimeric antigen receptor (CAR) modified T-cells led to complete response (CR) rates of 77% to 90% and minimal residual disease (MRD)-CR rates of 68% to 70% in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL).
Read More
Blinatumomab Granted Priority Review for Pediatric ALL
May 5th 2016The FDA has granted a priority review to a supplemental biologics license application that would extend the indication for blinatumomab to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Read More
Novel Targeted Therapies on Horizon in AML
April 12th 2016Multiple targeted therapies have shown promising signs of efficacy for patients with acute myeloid leukemia (AML), including the FLT3 inhibitor midostaurin and novel IDH inhibitors, with the ongoing potential for combination strategies in the future, according to Eytan M. Stein, MD.
Read More